Friday, April 29, 2016
Interventional Concepts, a CRO for innovative pharma, biotech and medtech development-stage companies proposing to conduct clinical trials in Colombia, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector nonprofit operating in the public interest and committed to transforming the global clinical research environment, have announced a strategic alliance, joining Interventional Concepts with current ACRES Allies in their efforts to build ACRES’ shared global clinical research system.
WCCT Global, a full-service CRO, is announcing the opening of an office and clinical operations in Seoul, Korea. With the expansion of operations into South Korea, the company is poised to further establish itself as a global CRO. The expansion is a part of the company’s efforts to increase its capacity for conducting high quality clinical research in one of Asia’s fastest-growing countries for biopharmaceutical development.
AbbVie has announced it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80% of SCLC patient tumors and is not present in healthy tissue. Registrational trials for third-line small cell lung cancer are expected to complete enrollment by the end of 2016.
Certara, a global biosimulation technology-enabled drug development company, has launched an e-learning platform through Certara University to satisfy the increased need for education in the burgeoning field of biosimulation or model-based drug development. With the addition of this new on-demand content, scientists from all over the world, with differing skill levels in biosimulation, will be able to access the educational assets developed by Certara’s scientific leaders.
The Weill Family Foundation and Joan and Sanford I. “Sandy” Weill have donated $185 million to establish the University of California San Francisco Weill Institute for Neurosciences, in an effort to accelerate the development of new therapies for diseases affecting the brain and nervous system, including psychiatric disorders.
Scientists are teaching computers to figure out why people accept or decline invitations to participate in clinical trials. Recruiting sufficient numbers of participants is a current challenge in medical research that can compromise results or stop some studies altogether.